Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, which is in Phase I/II clinical studies is a chimeric monoclonal antibody that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I clinical study, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; and PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases. Facet Biotech Corporation has a collaboration agreement with Biogen Idec Inc. The company is headquartered in Redwood City, California.

Vetoquinol S.A. was founded in 1933 and is based in Lure, France. Vétoquinol S A engages in the research and development, manufacture, marketing, and sale of medicines and nutraceuticals for animal health. It offers Marbocyl, an antibiotic for various species; Tolfédine and Tolfine anti-inflammatories for minimizing animal pain; and Prilium, an oral daily administration formula for cardiovascular treatment. The company’s products are used for dogs, cats, cattle, and pigs. It sells its products in Europe, North America, Africa, the Middle East, and the Pacific Asia. Vétoquinol S A was formerly known as Laboratoires Biochimiques de l’Est and changed its name to Vetoquinol S.A. in 1962.

Chesapeake Biological Laboratories (CBL) provides product development and commercial drug production services for pharmaceutical and biotechnology companies. It also manufactures experimental drugs for use in clinical trials. The company specializes in biopharmaceuticals, materials derived from naturally occurring biological substances. CBL's primary operations are sterilizing and filling liquid drugs and production lyophilization, the process of filling drug containers while limiting the product's exposure to room temperature. CBL is a wholly-owned subsidiary of Canadian biopharma firm Cangene.

CeMines Biologics, LLC company is working on more accurate, simple blood tests to diagnose lung, breast, prostate, and other cancers. The firm's CeMines Molecular FingerPrinting technology uses biostatistics to determine if disease biomarkers found in a patient's blood sample indicate the likelihood of cancer. Its lead product candidate, CeMines CellCorrect LAb, detects patterns of key antibodies that indicate cancer cells are present. Noted researcher Toomas Neuman, whose use of stem cells to treat Parkinson's disease triggered a national debate, founded the company in 2000 with several other officers of the company, which is led by CEO Richard Cavalli.

Green Foods Corporation company manufactures and sells nutritional products made from green barley grass and other natural ingredients. Of its lead products, its Green Magma provides healthy doses of vitamins, minerals, and antioxidants to promote overall wellness. Carrot Essence is beta-carotene and vitamin C supplement, and Magma Slim is a weight loss formula. Green Foods also makes products for pets, Barley Cat and Barley Dog. Dr. Yoshihide Hagiwara founded Green Foods Corporation, which sells its products throughout the US online and through brokers, in 1980.

Enzon Pharmaceuticals, Inc. company was founded in 1981 and is based in Bridgewater, New Jersey. Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing, manufacturing, and commercializing medicines for patients with cancer and other life-threatening conditions in the United States and internationally. Its products include Oncaspar, a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia; and DepoCyt, an injectable chemotherapeutic agent for the treatment of patients with lymphomatous meningitis. The company also offers Abelcet, a lipid formulation of amphotericin B used to treat immuno-compromised patients with invasive fungal infections; and Adagen, a PEGylated bovine adenosine deaminase enzyme (ADA) used to treat patients afflicted with a type of severe combined immunodeficiency disease, which is caused by the chronic deficiency of ADA. In addition, it licenses its PEGylation platform for products, such as PEG-INTRON, Pegasys, Macugen, and CIMZIA; and provides contract manufacturing services for various injectable products.Enzon is also developing PEG-SN38 for the treatment of colorectal, breast, and pancreatic cancer, as well as for non-Hodgkin's lymphoma; and HIF-1 alpha antagonist for the treatment of cancers and common solid tumors. Further, it offers Recombinant Human Mannose-Binding Lectin, a protein therapeutic to prevent and treat severe infections in individuals with low levels of MBL; and provides contract manufacturing services for various injectable products. The company has development and commercialization agreements with Santaris Pharma A/S; Schering-Plough; Sanofi-Aventis; Medac; Micromet; NatImmune A/S; Nektar; Pacira; and Cephalon France SAS. It markets its therapeutic products through its sales force that includes specialists in oncology, hematology, infectious disease, and various critical care disciplines.

Celgene Signal Research (also known as Celgene Research San Diego) wouldn't want it any other way. This Celgene division works to identify potential drug candidates with a focus on regulating genes and the production of disease-causing proteins. Much of its work has been to identify and map certain kinase and ligase proteins, which future Celgene drugs are then designed to inhibit. Celgene Signal Research's drug discovery programs target inflammatory diseases, as well as cancers such as leukemia.

Simplexity Health (formerly Cell Tech International) hopes that the algae growing in the fountain of youth is the secret. More specifically, the company scrapes up Aphanizomenon flos-aquae, a type of blue-green algae, out of Upper Klamath Lake, and stirs it into nutritional supplements, body care products, and nutrition bars. Calling it Super Blue Green Algae, the company's product line includes digestive aids, weight loss supplements, antioxidants, and powdered drink mixes. Simplexity Health sells its products through a multi-level, direct marketing program using a network of independent associates.

Otsuka Pharmaceutical Co. (OPC) is a manufacturer and distributor of pharmaceuticals, clinical testing and medical equipment, and food products. The company operates six business segments specializing in branded prescriptions, over-the-counter drugs, clinical nutritionals, diagnostic substances and devices, nutraceuticals, and skin care products ("cosmedics"). OPC's medicinal products include Mikelan eye drops for glaucoma treatment and Pletaal anti-platelet treatment. The company's line of nutraceutical consumer health products include FIBE-MINI dietary fiber supplement, Calorie Mate foods, and Pocari Sweat sports drink. Otsuka Pharmaceutical is part of the very diverse Otsuka Group.

Elan Corporation, plc company was founded in 1969 and is headquartered in Dublin, Ireland. Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. Elan’s operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain. EDT focuses on the specialty pharmaceutical industry, including specialized drug delivery and manufacturing. In September 2009, the Company and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer`s Immunotherapy Program (AIP).

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.